ICCC — ImmuCell Corporation

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Product Sales: $27.6 million for FY 2025, a 4.3% increase from 2024.
• Q4 Product Sales: $7.6 million, down 1.6% year-over-year, with domestic sales up 8.7% to $7 million and international sales down to approximately $600,000.
• Net Operating Profit: $1.6 million for FY 2025, a $3.3 million improvement from a loss in 2024.
• Gross Margin: Increased to 41% for FY 2025 from 30% in 2024; Q4 gross margin was 38%.
• Operating Expenses: Increased to $3 million in Q4 2025 from $2.2 million in Q4 2024; total operating expenses for FY 2025 were $9.8 million.
• Net Loss: Reduced to $1 million for FY 2025 from $2.1 million in 2024; basic net loss per share improved to $0.12 from $0.26.
• Cash Position: Ended 2025 with $3.8 million in cash; working capital increased to $13 million.

2. Strategic Updates and Business Highlights

• Management Changes: A new management team was hired in 2025.
• Manufacturing Capacity: Increased from 4.1 million units in 2024 to 4.6 million in 2025, with plans to further increase capacity to 5-6 million units.
• Focus on First Defense Franchise: The company is pivoting to maximize shareholder value from its First Defense product line, which addresses calf scours.
• Market Position: ImmuCell has captured approximately 15% of treated calves in the U.S. and 29% of the market spend in the calf scours category.
• Sales Expansion: New hires in sales and international market development are aimed at enhancing customer acquisition and market penetration.

3. Forward Guidance and Outlook

• Growth Confidence: Management expressed confidence in future growth due to resolved manufacturing issues and a strong market for calf health solutions.
• Sales Strategy: The company is shifting from managing product allocations to proactive customer outreach to drive top-line growth.
• Recurring Revenue: High customer loyalty and satisfaction are expected to contribute to recurring revenue, although specific churn metrics were not provided.

4. Bad News, Challenges, or Points of Concern

• International Sales Decline: International sales saw a significant drop, primarily due to order timing issues in Canada, which may impact overall growth.
• Re-Tain Write-Downs: A $2.7 million impairment charge related to the discontinued Re-Tain product line was noted, although no further large write-downs are anticipated.
• Operational Challenges: The company faced challenges in meeting demand due to prior backorders, which may affect short-term growth metrics.

5. Notable Q&A Insights

• Challenges Ahead: CEO Oliver Te Boekhorst identified capacity increase and proactive commercial activities as key challenges for 2026 and 2027.
• Future Write-Downs: CFO Timothy Fiori indicated that no significant additional write-downs for Re-Tain-related assets are expected.
• Recurring Revenue: While specific metrics were not provided, management emphasized high customer loyalty and satisfaction, suggesting a strong potential for recurring revenue despite past supply constraints.

This summary captures the essential financial performance, strategic direction, and challenges faced by ImmuCell Corporation as discussed during the Q4 2025 earnings call.